Transforming drug discovery and target validation from traditional to digital
Excision is developing CRISPR-based therapies to cure viral infectious diseases and improve the lives of chronically ill patients
Excision BioTherapeutics, Inc., is a biotechnology company developing CRISPR-based therapies to cure viral infectious diseases.
Excision is focused on improving the lives of chronically ill patients by eliminating viral genomes from infected individuals. By using CRISPR in unique ways, the company has already demonstrated the first functional cure for HIV in animals.
Excision’s cutting edge CRISPR gene therapy platform is built on technology licensed from the Doudna Lab at UC Berkeley and the Khalili Lab at Temple University.